Rearrangements of the high mobility group protein I-C (HMGI-C
Rearrangements of the high mobility group protein I-C (HMGI-
T he high mobility group protein I-C (HMGI-C) protein belongs to the HMGI protein family (1) , which also includes the HMG-I and HMG-Y proteins. HMGI proteins bind to the minor groove of AT-rich DNA sequences, thereby inducing a bend within the DNA (2, 3) . These proteins cannot stimulate initiation of transcription, but they can enhance promoter binding of transcription factors (3) (4) (5) .
The full activity of HMGI-Y proteins requires their two abilities: to bind directly to DNA and to enhance the binding of different transcription factors to DNA by protein-protein interaction (3, 4) . A similar mechanism of action has been reported for the HMGI-C protein (5) . The HMGI proteins may regulate the interaction of transcription factors with the basal transcription machinery, both positively and negatively, thereby controlling the transcriptional activity of several genes including IL-4 (6), and IL-2 receptor ␣-chain (IL-2 R␣) (7) .
The HMGI proteins have three separate DNA binding domains referred to as ''AT-hook'' motifs and a carboxyl-terminal region that contains a highly acidic tail (1) . Chromosomal translocations of 12q13-15, involving the HMGI-C gene, have been frequently detected in benign human tumors of mesenchymal origin (8, 9) . These chromosomal alterations lead to rearrangements and disordered expression of the HMGI-C gene. The HMGI-C modifications consist of the loss of the carboxylterminal tail and its fusion with ectopic sequences (8, 9) . We have previously shown that the truncation of HMGI-C, rather than its fusion with other genes, is responsible for cell transformation (10) . In fact, both the chimeric and truncated (deprived of the acidic tail) HMGI-C genes are able to neoplastically transform the murine fibroblast line NIH 3T3 (10) , and the acquisition of ectopic sequences does not increase the transforming ability of the truncated form of HMGI-C.
On this basis, we generated transgenic (TG) mice carrying a truncated HMGI-C (referred to as HMGI-C͞T mice). These mice developed a giant phenotype together with a drastic expansion of the retroperitoneal and s.c. white adipose tissues (11) .
Here, we report that HMGI-C͞T TG mice develop natural killer (NK)-T͞NK cell lymphomas starting from 12 months of age. We also demonstrate that both HMGI-C and its truncated form can stimulate the IL-2 and IL-15 pathways. Increased expression of these cytokines and their receptors in lymphoid tissues chronically stimulates T cell (mainly the NK-T cell subset) growth, eventually leading to the development of NK-T͞NK cell lymphomas.
Materials and Methods
Mice. TG mice for the HMGI-C truncated gene have been previously described (11) . They were maintained under specific pathogen-free conditions in our Laboratory Animal Facility (Thomas Jefferson University, Philadelphia, PA) according to institutional guidelines. As wild-type (WT) control animals, we used the offspring mice derived from the chimeric HMGI-C͞T mice that did not inherit the transgene.
Histopathological Analysis. For light microscopy, tissues were fixed by immersion in 10% formalin and embedded in paraffin by standard procedures. Five-micrometer sections were stained with hematoxylin-eosin. The antibodies used in immunohistochemistry were purchased from Dako.
Tissue Sampling and Flow Cytometric Analysis. Lymphocytes extracted from spleens, thymus, and lymph nodes from WT and TG mice were blocked with normal rat and goat IgG (Santa Cruz Biotechnology), stained with the f luorochrome-conjugated mAbs, and analyzed by flow cytometry (Coulter and Becton Dickinson) using the XL II System (Becton Dickinson). All of the antibodies used in f luorescence-activated cell sorter (FACS) analysis were anti-mouse monoclonals purchased from PharMingen.
For cytospin analysis, 7 ϫ 10 4 cells were spun onto microscope slides, air-dried, and stained with the May-Giemsa-Grunwald method.
Reverse Transcription (RT)-PCR Analyses. Tissues from TG animals were rapidly dissected, frozen on dry ice, and stored at Ϫ80°C until use. Total RNA was extracted as reported (11) . The PCR amplification was performed as described (11, 12) . The primers used to amplify IL-15, IL-2, IL-15 R␣, and the IL-2 R␣ mRNAs were described (12) . A set of primers specific for glyceraldehyde-3-phosphate dehydrogenase (GAPDH; ref. 11) was used as an internal control for the amount of cDNA tested. The PCR products were separated on agarose gels, blotted, and hybridized with specific oligonucleotide probes labeled with [␥-32 P]ATP.
Protein Extraction, Western Blotting, and Antibodies. Tissue samples from WT and TG mice were lysed and analyzed by Western blot following standard techniques. The primary antibodies against IL-15, IL-2, IL-2 R␣, IL-15 R␣, c-Kit, Janus kinase 3 (Jak-3), and pTyr were obtained from Santa Cruz Biotechnology. The antiactin antibody was from Sigma and the anti-neuronal cell adhesion molecule (anti-N-CAM) and anti-NK1.1 antibodies were from PharMingen.
Expression Vectors. The plasmids used in this study were the full-length of HMG-Y cDNA and the full length (pHMGI-C) and the truncated version of HMGI-C cloned in the pRC-CMV vector (10) or in the pcDNA-3 myc-HIS-tagged vector. The IL-15 promoter (13) and the IL-2 R␣ promoter region (Ϫ394 to ϩ108) were cloned in the pGL-3 reporter vector (Promega). pCMV-␤-gal was purchased from Invitrogen.
Cell Lines and Transfections. The 293 and A459 cell lines were grown in DMEM (GIBCO͞BRL) supplemented with 10% heat inactivated FCS (GIBCO͞BRL). Cells were transfected with the FuGENE-6 (Roche, Indianapolis, IN) with each pGL-3 construct with or without pHMGI-C, pHMGI-C͞T, or pHMG-Y expression vectors. In some experiments, pCMVp65 NF-B was used with or without the HMGI vectors. Cells were harvested 48 h posttransfection, and lysates were analyzed for luciferase activity. Transfection efficiency was normalized by using the ␤-galactosidase activity. All of the assays were performed in triplicate and were repeated in at least three independent experiments.
Production of Recombinant Proteins. The full-length or the truncated version of HMGI-C and HMG-Y cDNAs was cloned in the pET2c (Novagen). BL21͞DE3 cells transformed with each vector were grown in LB, induced with isopropyl ␤-D-thiogalactoside (IPTG), sonicated, and purified by using the His-Trap purification Kit (Amersham Pharmacia) following the manufacturer's instructions.
Electrophoretic Mobility-Shift Assay (EMSA). The oligonucleotides used in EMSA were: the IL-2 CD28RE and IL-2 CD28RE Mut described previously (14) ; the IL-2 R␣ and IL-2 R␣ Mut described before (7); and the IL-15 oligonucleotide spanning from base Ϫ84 to Ϫ52 of the IL-15 promoter region (13) . Recombinant proteins (5-100 ng) were incubated in the presence of radiolabeled oligonucleotide and poly(dCdG) (Sigma) as nonspecific competitor as previously described (7). In some experiments, a 50-or 100-fold excess of specific or nonspecific unlabeled competitor oligonucleotides was added. The DNAprotein complexes were resolved on 5% non-denaturing acrylamide gels and were visualized by exposure to autoradiographic films.
Culture of Fetal Liver Lymphocytes. Pregnant TG females were killed at day 14.5 postcoitum, and the embryos were collected and analyzed for the presence of the transgene. Fetal livers were excised, and precursor lymphocytes were extracted by mechanical disruption of the liver. Cells were resuspended in RPMI 1640 medium (GIBCO) supplemented with 10% FCS and B & T cell growth supplements (Origen, Austin, Tx) according to the manufacturer's instructions. After 12 days, cells were collected and analyzed for surface antigen expression by FACS analysis.
Results

HMGI-C͞T TG Mice Develop NK-T͞NK Cell Lymphomas.
Two lines of TG mice carrying a truncated HMGI-C gene were generated by a previously published embryonic stem cell strategy to obtain high expression levels of the transgene (11) . When the HMGI-C͞T mice were killed at 1 year of age, autopsy examination revealed that about 35% of the mice derived from both founder lines showed lymphoid pathology. Almost all (8 of 10) of the HMGI-C͞T mice killed at 24 months of age displayed similar pathology. In some animals, the size of the lymph nodes was more than 2 cm in diameter with a weight of almost 2 g, and the spleen reached a length of 4.0 cm and a weight of 5 g (Fig. 1A) . The histopathological analysis revealed tumors in the mesenteric lymph nodes, spleen, Peyer's patches, and to a lesser extent in the liver, mediastinal lymph nodes, thymus, and kidneys. The lymphomas were categorized as large cell lymphomas with typical histiocytic differentiation patterns or mixed cell lymphomas with a large cell component. These lymphomas were composed totally or partially of immature cells with large nuclei and prominent cytoplasm (Fig. 1C) . These features were confirmed by cytospin analysis of the same cases followed by May-Giemsa-Grunwald staining (Fig. 1B) . No evidence of lymphoma was found in WT mice younger than 23 months of age. In older control animals, we found very early follicular small cell-type lymphomas with clear B cell plasma cell differentiation (in about 20% of the cases), consistent with previously published data (15) . Immunohistochemical analysis showed that four of five large cell lymphomas from the TG mice were CD3 positive (Fig. 1D ) and CD20 negative (data not shown) and that the latter was negative for both antigens, indicating the presence of T cell lymphomas. FACScan analysis of lymphocytes isolated from WT or pathological spleen and lymph nodes using the CD3, B220, and CD19 anti-mouse antibodies confirmed the immunohistochemistry data. A double staining of lymphomatous spleen and lymph nodes ( Fig. 2A) revealed the presence of a CD3 ϩ ͞B220 ϩ ͞CD19 Ϫ population. In contrast, only 3-4% of cells were CD3 ϩ ͞B220 ϩ in splenocytes derived from WT animals (Fig. 2 A) . Because CD3 ϩ ͞B220 ϩ cells isolated from mouse bone marrow could be NK-T͞NK cell precursors, which are also positive for the typical NK-T cell surface antigen recognized by the NK1.1 antibody (16), we analyzed the lymphocytes isolated from WT spleens or pathological spleens and lymph nodes for the expression of NK1.1 (Fig. 2B) . Although in WT splenocytes the NK1.1-positive cells were about 8% of the total population (Fig. 2B) , the percentage of this population increased dramatically in pathological spleens and lymph nodes, reaching up to 80% of total lymphocytes (Fig. 2B) . A double staining FACS analysis of lymphocytes with CD3 and NK1.1 antibodies showed that most of the cells from pathological samples were CD3 ϩ ͞NK1.1 ϩ (Fig.  2C) , indicating the presence of T͞NK lymphocytes. Upregulation of NK1.1 antigen and other markers of the NK cells such as N-CAM and c-Kit in spleens and lymph nodes derived from the HMGI-C͞T mice were confirmed by using Western blot analysis (data not shown). On the basis of the results presented here, we classified these neoplasias as NK-T͞NK cell lymphomas. Proliferation of NK-T͞NK cells is known to be mainly dependent on the IL-2 and IL-15 pathways (17) . Thus, we analyzed the expression of the IL-2, IL-15, and their high affinity receptors (IL-2 R␣ and IL-15 R␣) in the lymphomatous tissues. A significant increase was observed in IL-2 (2-to 3-fold increase), IL-15 (3-to 5-fold), IL-2 R␣ (2-to 4-fold), and IL-15 R␣ (2-to 3-fold) protein levels in the neoplastic tissues in comparison with the normal spleen (Fig. 3A) . The up-regulation of IL-15 protein was also confirmed by immunohistochemistry (Fig. 3C) . RT-PCR analysis (Fig. 3B) paralleled the protein data, indicating that the induction occurs at the mRNA level, and suggesting that transcriptional control plays a major role in the regulation of the gene expression induced by the HMGI-C͞T transgene. The stimulation of the IL-2͞IL-15 receptor complex normally results in the activation of Jak-3 kinase (18, 19) . We then investigated whether the overexpression of IL-15 and͞or IL-2 and their receptors resulted in modification of the Jak-3 status. We found that all of the examined pathological tissues expressed higher Jak-3 protein levels than did normal spleen (Fig. 4A ). An increased phosphorylation of Jak-3 was also detected in the lymphomatous tissues (Fig. 4 B and C) , indicating that the intracellular pathway induced by IL-2 or IL-15 was also activated in HMGI-C͞T TG mice.
IL-15
Rather than IL-2 Is the Primary Target of HMGI-C Activity. It has been previously reported that HMGI-Y plays a pivotal role in the regulation of IL-2 and IL-2 R␣ promoters. Its overexpression enhances the transcription of both of these genes, thereby resulting in an increase of T cell proliferation (7, 14, 20) . We examined the possibility that HMGI-C was also able to bind to the promoter region of IL-2 and IL-2 R␣ genes. We demonstrated by EMSA that the HMGI-C recombinant protein binds with high affinity to the CD28 responsive element (CD28RE) of the IL-2 promoter and to the Ϫ137 to Ϫ64 promoter region of IL-2 R␣ as it occurs for the HMGI-Y protein (data not shown). To define the functional consequences of this in vitro DNAprotein interaction, we cotransfected a luciferase reporter construct containing the Ϫ394 to ϩ108 promoter region of the IL-2 R␣ gene with either the HMGI-C or HMGI-C͞T expression vectors. We demonstrated that both HMGI-C and HMGI-C͞T were able to activate the IL-2 R␣ promoter although HMGI-Y protein was more efficient (data not shown). Recent reports emphasize the role of IL-15 rather than IL-2 in the differentiation, survival, and proliferation of NK-T͞NK cells (21) . The knockout mice involving IL-15, IL-15 R␣, and IL-2 R␤ (which is necessary for the transduction of IL-15 signals in T and NK lymphocytes) developed defects in the NK-T͞NK population whereas the absence of IL-2 does not affect this population (22) (23) (24) . Thus, we evaluated the possibility that HMGI-C could regulate IL-15 transcription. The IL-15 promoter region contains many AT-rich regions to which HMGI-C protein might bind (13) . In EMSA experiments, we demonstrated that HMGI-C directly binds to the DNA sequence spanning the Ϫ84 to Ϫ52 region of the IL-15 promoter (Fig. 5A ). This binding was specific, as demonstrated by specific competition with three different oligonucleotides containing the HMGI binding sites (Fig. 5B, compare lanes 1-4 with lanes 5-8) . Interestingly, HMGI-C and HMGI-C͞T recombinant proteins had a very high affinity for this promoter region, because binding was visible when only 5 or 10 ng of proteins were added (data not shown). To determine whether this binding resulted in increased activity of the IL-15 promoter, we transfected the murine IL-15 promoter cloned in a luciferase reporter vector (13) with increasing amounts of HMGI-C and HMGI-C͞T into the A549 lung carcinoma cell line (which has been reported to express the IL-15 protein; ref. 25) . The expression of HMGI-C͞T enhanced the activity (2-to 3-fold) of the IL-15 promoter in a dose-dependent manner (Fig. 5C) . Interestingly, HMGI-C͞T protein was more effective than the WT form in enhancing the IL-15 promoter activity (data not shown). Moreover, cotransfection of pCMVp65 NF-B with HMGI-C͞T into the 293 cells resulted in a moderate but reproducible increase of IL-15 promoter activity over the pCMVp65 NF-B alone (Fig. 5D) . As reported previously (13), p65 NF-B by itself induced a strong activation of the IL-15 promoter.
Overexpression of the HMGI-C͞T Protein Increases the Number of
NK1.1 ؉ Cells in a Population of Cultured Fetal Liver Lymphocytes. Lu and coworkers (26) reported that fetal liver lymphocytes cultured in the presence of either IL-2 or IL-15 result in the development of a NK1.1 population and that the two cytokines had a synergistic effect in this process. To determine whether the HMGI-C͞T overexpression increased the ability of fetal lym- phocytes to differentiate into NK-T͞NK cells, we cultured fetal liver lymphocytes extracted from WT and TG embryos for 12 days in a mixture of IL-2, IL-4, and IL-6 that allows the growth of both T and B cells. The mixed population was then analyzed for the expression of CD44 (as a positive control) and NK1.1 surface antigens. As shown in Fig. 6 , the CD44 antigen is widely expressed in both WT and TG derived fetal lymphocytes. In contrast, a significantly increased number of NK1.1-positive cells was found in lymphocytes derived from the liver of HMGI-C͞T mice when compared with the control mice (Fig. 6 ).
Discussion
Here, we report that 35% of TG mice carrying a truncated HMGI-C gene develop massive lymph node enlargement and splenomegaly with the presence of immature atypical lymphocytes starting from 12 months. Almost all of the TG mice older than 24 months showed this pathology. Immunohistochemical and FACS analyses showed that these cells expressed the CD3, NK1.1, N-CAM, and c-Kit antigens, suggesting the diagnosis of NK-T͞NK cell lymphoma.
In humans, the NK-T͞NK cell lymphomas have been only recently classified as an autonomous pathology with a typical surface antigen expression, including CD3 and the CD56 (N-CAM) antigens, and characteristic localization (27) . The disease usually starts in the rhinopharyngeal region (nasal NK lymphomas) or in intestinal and cutaneous regions (nasal-type NK lymphomas). In some cases, lymphoma-leukemia pathology was reported with dissemination of the disease to different lymphoid and extra lymphoid organs (28) . Accordingly, we found that in mice this pathology was usually localized to the gastrointestinal tract and, in early cases, the localization was primarily observed in Peyer's patches. As in humans, we found in some cases a very aggressive pathology with the involvement of the spleen, the liver, and many other organs, such as lung and pancreas.
An essential role for IL-15 and IL-15 R␣ and a contributing role for IL-2 and IL-2 R␣ in NK-T͞NK cell proliferation has been demonstrated (29) (30) (31) (32) . IL-15 binds with high affinity to a receptor complex composed of the IL-15 R␣ chain and IL-2 R␤ and -␥ chains (33) . The specificity of the binding is due to the presence of the IL-15 R␣ (33). NK and T͞NK cells express the shared ␤ and ␥ chains as well as the high affinity IL-2 and IL-15 R␣ subunits. Comparative studies of IL-2 R␣ and IL-2͞15 R␤-deficient mice suggest that IL-15 rather than IL-2 might be important for the differentiation of T͞NK cells and intraepithelial lymphocytes (23, 24) . IFN regulatory factor (IRF-1)-deficient mice lack NK cells because of the inability of their bone marrow stromal cells to elaborate IL-15, suggesting a unique role for IL-15 in NK cell development (34) . Finally, IL-15 and IL-15 R␣-deficient mice (24) are generally healthy and lymphopenic and specifically lack NK, T͞NK, IELs, and activated CD8 ϩ memory phenotype T cells. Conversely, IL-2 and IL-2 R␣-deficient mice accumulate activated T and B cells and prematurely die of autoimmune disease (35, 36) .
Here, we demonstrated that in vivo overexpression of HMGI-C͞T protein led to overexpression of IL-2 and IL-15 and their receptors mainly through transcriptional activation. Moreover, in HMGI-C͞T TG mice the induction of IL-15 expression was greater than IL-2 expression (3-to 5-fold and 2-to 3-fold, respectively). Accordingly, we demonstrated, by EMSA, that HMGI-C and HMGI-C͞T proteins were able to bind to the IL-15 promoter region with greater avidity than did the HMGI-Y protein. In contrast, the promoter regions of IL-2 and IL-2 R␣ were bound better by the HMGI-Y than by the HMGI-C protein.
According to this result, the TG mice overexpressing the HMGI-Y gene developed lymphomas with a lower frequency and longer latency period (data not shown). Using the IL-15 and IL-2 R␣ promoter regions cloned into luciferase reporter vectors, we also demonstrated that HMGI-C͞T and HMGI-C stimulate the transcription of IL-15 better than HMGI-Y whereas the latter protein was more effective in the stimulation of the IL-2 R␣ promoter. These data strongly suggest that the activation of the IL-15 promoter activity associated with HMGI-C͞T overexpression mainly accounts for the onset of NK lymphomas in the HMGI-C͞T TG mice. Finally, some pieces of evidence emerging from our studies with HMGI-Y and HMGI-C͞T TG mice confirm a central role for the HMGI-C͞T protein in the onset of NK͞T-NK cell lymphomas in a mouse model. In fact, HMGI-C͞T TG mice, generated by the microinjection of the same construct directly into fertilized mouse eggs, resulted in a significantly lower expression of the transgene expression when compared with the embryonic stem cell-mediated strategy (11) . Accordingly, the phenotype was less prominent in the first rather than the second mouse line. In fact, in HMGI-C͞T TG mice derived from the classical approach, the onset of this pathology is at 15 months of age and a lower proportion of mice develops the lymphopathology (data not shown).
We have shown that the increase in levels of IL-2 and IL-15 proteins and their receptors results in Jak-3 activation. We hypothesized that this increased activity may be responsible for the NK-T͞NK expansion. This hypothesis was based on several pieces of experimental evidence. In vivo administration of IL-15 was reported to protect mice from lethal multisystem apoptosis induced by anti-fas antibody (37) . Moreover, Caligiuri and coworkers (38) proposed that IL-15 might function as an NK cell survival factor by the maintenance of Bcl-2 protein expression, thereby preventing NK cell apoptosis. TG mice overexpressing human IL-15 showed an increase of NK cells and memory T cells because of the ability of IL-15 to selectively prolong the survival of memory T cells by blocking activation of T cell death mediated by a process involving IL-2 (39). Finally, TG mice overexpressing murine IL-15 showed an early expansion in NK and CD8 ϩ T lymphocytes and developed fatal T͞NK lymphocytic leukemia between 3 and 8 months of age (40) . Collectively, these data support the emerging notion that IL-2 and IL-15 expression must be balanced to achieve appropriate cellular immunity during immune responses.
Our data obtained by using embryonic liver lymphocytes from TG or WT embryos seem to support our hypothesis. We demonstrated that, in the presence of both B and T cell growth factors, HMGI-C͞T embryonic lymphocytes developed with a statistical higher percentage into NK1.1-positive cells when compared with those in the WT mice. This result suggests that overexpression of HMGI-C͞T predisposed stem cell lymphocyte precursors to differentiate into NK-T͞NK cells and͞or protected them from apoptosis. Both of these effects may be accounted for by HMGI-C͞T-mediated induction of IL-15 overexpression. Taken as a whole, our data indicate that the HMGI-C͞T-mediated induction of IL-15 overexpression leads to NK-T͞NK lymphomas in the HMGI-C͞T TG mice.
